Daily Mail calls one teen’s 28-day trial a cure
Daily Mail
Miracle new 'Ozempic of autism' drug cured my son's worst symptoms... just days after taking his first pill: Breakthrough treatment poised to explode across globe as clinical trial leader says he 'almost fainted' at the resultsRead it where it was published
A laughing face and ‘Miracle’ hand you a parent’s dream finished in days. The proof is one teenager’s 28 days in 2015, and the hope works hardest for the company still testing the drug.
On October 26 the Daily Mail told how Joshua Turteltaub took Yamo Pharmaceuticals’ experimental autism drug L1-79 for 28 days in a 2015 trial. The headline says it “cured” him. The text says he regressed when he stopped.
What they said
On October 26, 2026, the Daily Mail reported a mother’s account of her son’s 28 days on L1-79, an experimental autism drug in phase 2 trials with FDA Fast Track designation.
Daily MailDr Eric Bartky, psychiatrist and principal investigator in two FDA trials of L1-79Oct 26, 2026
“I almost fainted because he had never said anything. He had never said words or those words, ever.”
Read it where it was publishedDaily MailLinda Turteltaub, mother of trial participant Joshua TurteltaubOct 26, 2026
“We've had to go back on all kinds of meds for his anxiety. You can't believe how many meds he's on”
Read it where it was publishedDaily MailLinda TurteltaubOct 26, 2026
“I'm a lawyer, and even I would sign anything to get him back on”
Read it where it was publishedYahoo News
Dad says autism ‘miracle drug’ drastically and immediately improved his son’s severe symptoms
Read it where it was published
“Miracle” A miracle cannot be argued with, only hoped for. It stands unquoted, in the outlet’s own voice, where a trial phase and a patient count would go.
“cured my son's worst symptoms” The mother’s word, set at the top. The article’s 26th paragraph says Joshua took the drug for 28 days in 2015 and ‘regressed’ as soon as he had to stop.
“clinical trial leader says he 'almost fainted' at the results” The leader treated Joshua for eight years and recommended the trial. In the article his faint came at Joshua’s goodbye in his office, not at trial-wide results.
“I almost fainted” The words behind the faint: one young man speaking as he left the office, a few weeks into treatment. Moving, and one patient.
“go back on all kinds of meds” The mother’s own account of what came after the trial ended. The headline keeps the first week and leaves this out.
“‘miracle drug’” Yahoo puts ‘miracle drug’ in quotation marks and in a father’s mouth. The Mail prints Miracle with no quotation marks, as its own word.
The analysis
The headline’s cure has one patient. Joshua Turteltaub was 16 when he took L1-79 in a 2015 trial, and he is 27 now. The 26th paragraph says he took it for 28 days and ‘regressed’ as soon as he had to stop. His mother says he is back on “all kinds of meds”. The headline’s “just days” is “one week” in the eighth paragraph. The tell is plain: one family’s story stands where the trial’s count should be.
The second proof is a title. The “clinical trial leader” is Dr Eric Bartky, the psychiatrist who treated Joshua for eight years, recommended the trial and was a principal investigator in two FDA trials. In the article, his faint came when Joshua said goodbye leaving his office. The headline attaches it to “the results”. The habit it counts on: the title does the proving, so a doctor’s surprise reads as data. The “Ozempic” label, the fifth paragraph says, came from “others who have since tried the investigational drug”.
Then the big words. “Miracle”, “Breakthrough” and “explode across globe” are glittering words: no one argues against a miracle, so it asks for hope instead of a figure. The article’s own facts are smaller: phase 2 trials, 116 patients across three studies, and a Fast Track status that “doesn’t shorten the clinical trials themselves”. The headline names no company, no count of who improved and no payer. Excitement about an unapproved drug is worth most to its owner, Yamo Pharmaceuticals.
The words. The headline’s “poised to explode across globe” writes a future as a present fact. The article’s own status line is phase 2 with Fast Track, which it says does not shorten the trials.
The money. Yamo Pharmaceuticals owns L1-79. The headline carries 0 company names, 0 prices and 0 counts of patients helped out of 116. The reader gets a mother, a doctor and a miracle.
From the book
The Authority Override
The headline calls Dr Bartky the “clinical trial leader” and moves his faint from one patient’s goodbye to “the results”, so a title stands in for the trial’s numbers.
Chapter 9, The Cognitive Cascades
The Vividness Virus
One laughing young man and a mother’s “cured” outweigh 116 trial patients whose outcomes the headline never counts.
Chapter 9, The Cognitive Cascades
Your move
- The Master Question: this is built to make you feel hope for a child who could not speak, and fast. Why now? Hope does its work before a trial’s numbers arrive. Real facts are boring: phase 2, 116 patients, no count of who improved.
- Does it touch you? If you love an autistic child, it may. Then the decision is a plan built on a trial’s results, never a feeling built on one family’s week. If not, it is weather: watch it pass without bleeding or feeding.
- Your nudge: name what pulled you, ‘Miracle’, ‘cured’ or the doctor who almost fainted, and the belief it pressed on: that medicine has failed families like yours, or that every cure is hype. The same line pulls those two readers opposite ways.
Sources Daily MailYahoo News